Browse
related articles
Neopharma to produce Merck's Euthyrox, Glucophage locally
- United Arab Emirates: Monday, December 03 - 2012 at 04:34
BR Shetty, the managing director and chief executive of Neopharma, has said the Abu Dhabi-based company plans to invest up to Dhs300m over the next year to locally produce Merck-brand medication, Gulf News has reported. This follows the signing of an agreement with Merck Serono, a division of Merck KGaA of Germany, to manufacture Euthyrox, a hormone therapy requiring a very stringent sterile environment for production and packaging, and Glucophage, a standard oral treatment for people suffering from type 2 diabetes that helps control blood sugar levels. "The production agreement with Merck for the two brand products is for five years. The funding will be through my own sources. Over the next five years, we are looking to invest up to Dhs500m for producing branded medicines at Neopharma," Shetty said.
Related Content
Article Options
Disclaimer »
The information comprised in this section is not, nor is it held out to be, a solicitation of any person to take any form of investment decision. The content of the AMEinfo.com Web site does not constitute advice or a recommendation by Mediaquest FZ LLC and should not be relied upon in making (or refraining from making) any decision relating to investments or any other matter. You should consult your own independent financial adviser and obtain professional advice before exercising any investment decisions or choices based on information featured in this AMEinfo.com Web site.
Mediaquest FZ LLC can not be held liable or responsible in any way for any opinions, suggestions, recommendations or comments made by any of the contributors to the various columns on the AMEinfo.com Web site nor do opinions of contributors necessarily reflect those of Mediaquest FZ LLC.
In no event shall Mediaquest FZ LLC be liable for any damages whatsoever, including, without limitation, direct, special, indirect, consequential, or incidental damages, or damages for lost profits, loss of revenue, or loss of use, arising out of or related to the AMEinfo.com Web site or the information contained in it, whether such damages arise in contract, negligence, tort, under statute, in equity, at law or otherwise.
